GI 10N
Alternative Names: GI-10NLatest Information Update: 22 Nov 2022
At a glance
- Originator GI Innovation
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Nov 2022 Preclinical trials in Cancer in South Korea (unspecified route), before November 2022 (GI Innovation pipeline, November 2022)
- 16 Apr 2020 Early research in Cancer in South Korea (GI Innovation pipeline, April 2020)
- 16 Apr 2020 GI Innovation plans GLP-toxicology studies for Cancer, in 2022 (GI Innovation pipeline, April 2020)